Navigation Links
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Date:5/21/2009

Access to Late-Stage, First-in-Class Prostate Cancer Treatment Strengthens Presence in Oncology

NEW BRUNSWICK, N.J., and LOS ANGELES, May 21 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Cougar Biotechnology, Inc. (Nasdaq: CGRB), a development stage biopharmaceutical company with a specific focus on oncology, today announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0 billion in a cash tender offer.

Cougar Biotechnology, which has compounds in development for the treatment of prostate cancer, as well as breast cancer and multiple myeloma, will work with Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., a Johnson & Johnson company.

Under the terms of the agreement, Johnson & Johnson will initiate a tender offer, through a new wholly-owned subsidiary, to purchase all outstanding shares of Cougar Biotechnology at $43 per share. The tender offer is conditioned on the tender of a majority of the outstanding shares of Cougar Biotechnology's common stock. The closing is conditioned on clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The $970 million estimated net value of the transaction is based on Cougar Biotechnology's 20.8 million shares outstanding, net of estimated cash on hand at closing. The boards of directors of both Johnson & Johnson and Cougar Biotechnology have approved the transaction.

Cougar Biotechnology is currently conducting two Phase III trials for abiraterone acetate, a late stage, first-in-class compound for the treatment of prostate cancer. The first Phase III trial is testing abiraterone acetate in
'/>"/>

SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
2. Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
3. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
4. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
5. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
6. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
7. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
8. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
9. Migenix averts proxy contest; reaches agreement with DJohnson holdings
10. Craig Johnson Joins Ardea Biosciences Board of Directors
11. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 ... patient registry platform, announced that three PatientCrossroads-based ... dystrophies; the Phelan-McDermid Syndrome International Registry; and ... Syndrome—have been awarded contracts by the Patient-Centered ... the creation of a new health data ...
(Date:7/13/2014)... discovery 30 years ago of soccer-ball-shaped carbon molecules called ... Now, there appears to be a new ball on ... and Tsinghua University in China have shown that a ... cage similar to a carbon buckyball. It,s the first ... matter of speculationdoes indeed exist. , "This is the ...
(Date:7/13/2014)... Dallas, TX (PRWEB) July 13, 2014 ... Silver Industry” is a professional and in-depth study on ... Global and China. , The report provides a basic ... chain structure. Global market analysis and Chinese domestic market ... trends and competitive landscape of the market. A comparison ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
Breaking Biology Technology:PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3
... of assay of cell-mediated ... immunity, ... data on the monitoring of cell-mediated immunity (CMI) in adult patients,undergoing heart ... demonstrated that ImmuKnow(R) values,appear to closely reflect the immune function of the ...
... REHOVOT, Israel and JERSEY CITY, New Jersey, April ... leader in,the development of microRNA-based diagnostics and therapeutics, ... upcoming annual AACR,conference in San Diego. The posters ... and how they may be applied to develop,objective ...
... Zentaris Inc.,(Nasdaq: AEZS TSX: AEZ;), a global biopharmaceutical ... that David J. Mazzo, Ph.D.,has resigned as President ... the,Board of Directors of AEterna Zentaris, effective immediately. ... of AEterna Zentaris, has been,appointed as the interim ...
Cached Biology Technology:Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 2Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5AEterna Zentaris Announces Changes to its Management Team 2
(Date:7/10/2014)... SPRINGS, Colo. , June 27, 2014 /PRNewswire/ ... that the National Institute of Standards and Technology ... 10 of its academic research and forensic science ... (FSSB).  The Board is an element of the ... AAFS members are among the first appointments made ...
(Date:7/10/2014)... -- Aware, Inc. (NASDAQ: AWRE ), a leading ... June 26, 2014 that its Board of Directors had ... or approximately $40 million in total.  The Board established ... payment date of July 24, 2014.  The Company was ... ex-dividend date for this special cash dividend.  An ex-dividend ...
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... Wallace, PhD, a pioneering genetics researcher who founded the ... 2012 Genetics Prize of The Gruber Foundation. Wallace is ... groundbreaking achievements in helping science understand the role of ... and as markers for human evolution., He will receive ...
... , ,Oligonucleotide technologies, such as siRNA, tap into ... efficiently regulate gene expression. As such, they have ... therapeutic options for disease targets previously considered un-druggable ... despite the promise, clinical development has been hindered ...
... a half-dozen palladium- and iron-based catalysts for cleaning up the ... TCE far faster than iron -- up to a billion ... in a new study in the August issue of the ... trichloroethene, is a widely used chemical degreaser and solvent that,s ...
Cached Biology News:$500,000 Gruber Foundation Genetics Prize goes to Philadelphia scientist 2Oligonucleotide Delivery: Biology, Engineering and Development Conference 2Oligonucleotide Delivery: Biology, Engineering and Development Conference 3Palladium-gold nanoparticles clean TCE a billion times faster than iron filings 2
... Services include: ,ICC and IHC Protocol ... Analyses ,Antibody Screenings in Animal or ... Labeling of Cells and Tissues ,Peroxidase, ... ,Light, Fluorescent, or Electron Microscopy ,Protein ...
Use our experts and resources to develop reagent systems for your applications....
Request Info...
Request Info...
Biology Products: